ATYR
aTyr Pharma, Inc. NASDAQ Listed May 7, 2015$0.47
+4.37%
vs $0.45
Mkt Cap $43.7M
52w Low $0.40
1.2% of range
52w High $6.61
50d MA $0.65
200d MA $0.95
P/E (TTM)
-0.6x
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.2x
ROE
-109.8%
P/FCF
-0.7x
RSI (14)
34.90
ATR (14)
$0.04
Beta
0.65
50d MA
$0.65
200d MA
$0.95
Avg Volume
3.7M
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
10240 Sorrento Valley Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.16 | -0.11 | +31.2% | 0.50 | +0.4% | +3.1% | -7.0% | +9.9% | -0.4% | -7.3% | — |
| Mar 5, 2026 | AMC | -0.18 | -0.14 | +22.2% | 0.90 | -3.1% | -8.7% | +9.2% | +4.0% | -1.5% | -5.9% | — |
| Nov 6, 2025 | AMC | -0.20 | -0.26 | -30.0% | 0.77 | -2.6% | +6.0% | -3.3% | -0.3% | -8.2% | -1.3% | — |
| Aug 7, 2025 | AMC | -0.18 | -0.22 | -22.2% | 5.24 | +0.0% | +1.1% | +5.8% | -6.8% | -1.5% | -3.1% | — |
| May 7, 2025 | AMC | -0.19 | -0.17 | +10.5% | 3.16 | -1.6% | +5.7% | -1.8% | -1.2% | +2.2% | -8.5% | — |
| Mar 13, 2025 | AMC | -0.23 | -0.18 | +21.7% | 3.99 | -8.3% | -0.5% | +1.0% | -3.5% | -0.8% | -2.1% | — |
| Nov 7, 2024 | AMC | -0.22 | -0.23 | -4.5% | 3.10 | -1.6% | +0.6% | +7.7% | +3.9% | +0.9% | -9.4% | — |
| Aug 13, 2024 | AMC | -0.22 | -0.23 | -4.5% | 1.74 | +5.7% | +6.3% | +8.1% | -4.5% | -1.0% | -1.6% | — |
| May 2, 2024 | AMC | -0.24 | -0.23 | +4.2% | — | — | — | — | — | — | — | — |
| Mar 14, 2024 | AMC | -0.24 | -0.25 | -4.2% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.23 | -0.20 | +13.3% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.28 | -0.22 | +19.7% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | -0.35 | -0.29 | +18.5% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $0.77 | $0.75 | -2.6% | +6.0% | -3.3% | -0.3% | -8.2% | -1.3% |
| Sep 16 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $1.01 | $1.08 | +6.9% | +6.9% | -5.6% | +2.9% | -5.5% | +5.8% |
| Sep 16 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $1.01 | $1.08 | +6.9% | +6.9% | -5.6% | +2.9% | -5.5% | +5.8% |
| Sep 15 | LUCID CAPITAL MARKETS | Downgrade | Buy → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | +6.9% | -5.6% | +2.9% | -5.5% |
| Sep 15 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $6.03 | $1.26 | -79.1% | -83.3% | +6.9% | -5.6% | +2.9% | -5.5% |
| Sep 15 | Jones Trading | Downgrade | Buy → Hold | — | $6.03 | $1.26 | -79.1% | -83.3% | +6.9% | -5.6% | +2.9% | -5.5% |
| Sep 15 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | +6.9% | -5.6% | +2.9% | -5.5% |
| Sep 15 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $6.03 | $1.26 | -79.1% | -83.3% | +6.9% | -5.6% | +2.9% | -5.5% |
| Aug 22 | Jefferies | Maintains | Buy → Buy | — | $4.95 | $5.11 | +3.2% | +8.1% | -3.6% | -0.4% | +0.6% | +3.5% |
| Jun 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.17 | $5.49 | +6.2% | +1.0% | -4.6% | +6.6% | -3.8% | +3.9% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.50 | +2.0% | -4.6% | +4.1% | +0.6% | +1.3% | +0.9% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.30 | +0.9% | +5.2% | +1.5% | +7.4% | +1.3% | -1.3% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.99 | $3.66 | -8.3% | -0.5% | +1.0% | -3.5% | -0.8% | -2.1% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.53 | $3.60 | +2.0% | -6.8% | -3.6% | -4.7% | +1.3% | -1.0% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.56 | +0.0% | -6.5% | +0.0% | -1.8% | +2.8% | +5.1% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.32 | $3.47 | +4.5% | +0.0% | -5.7% | -0.3% | -2.6% | +1.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.88 | +1.6% | +8.1% | -4.5% | -1.0% | -1.6% | +1.1% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $1.74 | $1.84 | +5.7% | +6.3% | +8.1% | -4.5% | -1.0% | -1.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $2.02 | +2.0% | -1.5% | -6.2% | +2.7% | -0.5% | -4.8% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.70 | +3.7% | +13.4% | +0.5% | +3.2% | +15.5% | -0.4% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | HC Wainwright& Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | SCHIMMEL PAUL | — | Buy | 100,000 | $0.50 | $50K | 779,143 | +11.30% | +2.58% |
8-K
aTyr Pharma, Inc. -- 8-K Filing
Jun 8
8-K · 2.02
!! High
aTyr Pharma, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K · 2.02
!! High
aTyr Pharma, Inc. -- 8-K 2.02: Earnings Results
May 11
8-K
aTyr Pharma, Inc. -- 8-K Filing
aTyr Pharma expects FDA feedback on its Phase 3 efzofitimod lung sarcoidosis study in April 2026, while advancing its systemic sclerosis program toward enrollment completion.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 14,706,843 | $11M | — | Mar 2026 |
| 2 | Ubs Group Ag | 3,867,213 | $3M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,812,132 | $3M | New | Mar 2026 |
| 4 | Morgan Stanley | 2,806,018 | $2M | Added | Dec 2025 |
| 5 | Millennium Management | 1,641,246 | $1M | New | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 1,144,565 | $893K | Added | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 866,744 | $676K | Added | Mar 2026 |
| 8 | Northern Trust Corp | 711,105 | $555K | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 569,227 | $444K | New | Mar 2026 |
| 10 | Aqr Capital Management Llc | 496,018 | $387K | Reduced | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 303,559 | $237K | Added | Mar 2026 |
| 12 | Eversource Wealth Advisors, Llc | 581,138 | $219K | Added | Mar 2026 |
| 13 | Nuveen, Llc | 229,284 | $179K | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 193,531 | $151K | — | Mar 2026 |
| 15 | Jane Street Group, Llc | 188,149 | $147K | Reduced | Dec 2025 |
| 16 | Marshall Wace, Llp | 138,118 | $108K | New | Mar 2026 |
| 17 | Victory Capital Management Inc | 88,436 | $69K | Reduced | Mar 2026 |
| 18 | Adar1 Capital Management, Llc | 50,685 | $40K | New | Mar 2026 |
| 19 | Citadel Advisors Llc | 47,372 | $37K | New | Mar 2026 |
| 20 | Wells Fargo & Company/mn | 46,540 | $36K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$43.7M
Enterprise Value
-$35.0M
P/E (TTM)
-0.64x
Forward P/E
—
PEG Ratio
0.14x
P/B
0.65x
P/S
230.11x
P/FCF
-0.70x
EV/EBITDA
—
Shares Out
93.0M
Financials (TTM)
Revenue
$190K
Net Income
-$70.0M
EBITDA
-$68.7M
Free Cash Flow
-$62.1M
Op Cash Flow
-$62.0M
EPS Basic
$-0.80
EPS Diluted
$-0.73
EPS Forward
$-0.59
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$94.2M
Total Liab.
$26.9M
Total Equity
$67.3M
Cash
$78.7M
LT Debt
$0
Book Value/Sh
$0.72
Debt/Equity
0.18x
Current Ratio
5.30
Quick Ratio
5.30
Returns & Growth
ROE
-109.8%
ROA
-79.7%
ROIC
-96.5%
Rev Growth YoY
-19.1%
EPS Growth YoY
+7.0%
Price Returns
2W
-3.1%
1M
-32.8%
3M
-43.5%
6M
-30.5%
12M
-87.9%
Technicals
52W High
$6.61
52W Low
$0.40
50d MA
$0.65
200d MA
$0.95
RSI (14)
34.90
ATR (14)
$0.04
Beta
0.65
Avg Volume
3.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.13
High
$17.00
Low
$1.00
Median
$1.25
Data updated apr 24, 2026 7:44pm
· Source: financialmodelingprep.com